Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody,OncoImmunology

当前位置： X-MOL 学术 › Oncoimmunology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
OncoImmunology ( IF 7.2 ) Pub Date : 2023-10-16 , DOI: 10.1080/2162402x.2023.2255041
Hayat Bähr-Mahmud ₁ , Ursula Ellinghaus ₁ , Christiane R Stadler ₁ , Leyla Fischer ₁ , Claudia Lindemann ₁ , Anuhar Chaturvedi ₁ , Jan Diekmann ₁ , Stefan Wöll ₁ , Imke Biermann ₁ , Bernhard Hebich ₁ , Caroline Scharf ₁ , Manuela Siefke ₁ , Alexandra S Roth ₁ , Martin Rao ₁ , Kerstin Brettschneider ₁ , Eva-Maria Ewen ₁ , Uğur Şahin _{1,

2} , Özlem Türeci _{1,

3}

Affiliation

IMAB362/Zolbetuximab, a first-in-class IgG1 antibody directed against the cancer-associated gastric-lineage marker CLDN18.2, has recently been reported to have met its primary endpoint in two phase...

中文翻译：